Advertisement
Advertisement
CATX
Perspective Therapeutics, Inc.
0.84
USDSponsored
+0.05
+6.54%
Nov 06, 15:45 UTC -5
Closed
After-Market
0.87
+0.03
+3.21%
Perspective Therapeutics, Inc. (CATX) Earnings
CATX Earnings Reports
Positive Surprise Ratio
CATX beat 24 of 36 last estimates.
67%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Perspective Therapeutics, Inc. earnings per share and revenue
On Aug 10, 2026, CATX reported earnings of -0.22 USD per share (EPS) for Q2 26, beating the estimate of -0.26 USD, resulting in a 15.87% surprise. Revenue reached 81.00 thousand, compared to an expected 84.81 thousand, with a -4.50% difference. The market reacted with a +6.00% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Perspective Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Perspective Therapeutics, Inc. reported EPS of -$0.22, beating estimates by 15.87%, and revenue of $81.00K, -4.5% below expectations.
How did the market react to Perspective Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved up 6%, changed from $3.00 before the earnings release to $3.18 the day after.
When is Perspective Therapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Perspective Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Perspective Therapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.